Comparative Pharmacology
Head-to-head clinical analysis: FORBAXIN versus PROLOPRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORBAXIN versus PROLOPRIM.
FORBAXIN vs PROLOPRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FORBAXIN is a prodrug of the active moiety cefditoren, a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Inhibits bacterial dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial DNA, RNA, and protein synthesis.
IV: 500 mg every 12 hours, infused over 30 minutes.
100 mg orally twice daily or 200 mg orally once daily.
None Documented
None Documented
8-12 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Terminal elimination half-life is 8-10 hours in normal renal function; prolonged (>20 hours) in significant renal impairment.
Renal (60-70% unchanged), biliary/fecal (20-30%)
Primarily renal (80-90% as unchanged drug); less than 5% as metabolites; fecal excretion negligible.
Category C
Category C
Antibiotic
Antibiotic